David Miles

David Miles

Auto-generated profile, based on publicly available information

David Miles

Imperial College London

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2012 in The Economic Journal
Verified
Journal Article
Closed access
PDF file
MJMichael Joyce
Michael Joyce
DMDavid Miles
David Miles
ASAndrew Scott
Andrew Scott
DVDimitri Vayanos
Dimitri Vayanos

6 June 2012 in The Economic Journal
Verified
Journal Article
Closed access
PDF file
DMDavid Miles
David Miles
JYJing Yang
Jing Yang
GMGilberto Marcheggiano
Gilberto Marcheggiano

1 January 1999 in The Economic Journal
Verified
Journal Article
Closed access
PDF file
DMDavid Miles
David Miles

1 November 1993 in The Economic Journal
Verified
Journal Article
Closed access
DMDavid Miles
David Miles

13 August 2020 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
DMDavid K. Miles
David K. Miles
MSMichael Stedman
Michael Stedman
AHAdrian Heald
Adrian Heald
Introduction The COVID‐19 pandemic has transformed lives across the world. In the UK, a public health driven policy of population ‘lockdown’ has had enormous personal and economic impact. Methods We compare UK response and outcomes with European countries of similar income and healthcare resources. We calibrate estimates of the economic costs as different % loss in Gross Domestic Product (GDP) against possible benefits of avoiding life years lost, for different scenarios where current COVID‐19 mortality and comorbidity rates were used to calculate the loss in life expectancy and adjusted for their levels of poor health and quality of life. We then apply a quality‐adjusted life years (QALY) value of £30,000 (maximum under national guidelines). Results There was a rapid spread of cases and significant variation both in severity and timing of both implementation and subsequent reductions in social restrictions. There was less variation in the trajectory of mortality rates and excess deaths, which have fallen across all countries during May/June 2020. The average age at death and life expectancy loss for non‐COVID‐19 was 79.1 and 11.4 years respectively while COVID‐19 were 80.4 and 10.1 years; including adjustments for life‐shortening comorbidities and quality of life plausibly reduces this to around 5 QALY lost for each COVID‐19 death. The lowest estimate for lockdown costs incurred was 40% higher than highest benefits from avoiding the worst mortality case scenario at full life expectancy tariff and in more realistic estimations they were over 5 times higher. Future scenarios showed in the best case a QALY value of £220k (7xNICE guideline) and in the worst‐case £3.7m (125xNICE guideline) was needed to justify the continuation of lockdown. Conclusion This suggests that the costs of continuing severe restrictions are so great relative to likely benefits in lives saved that a rapid easing in restrictions is now warranted.

1 June 1992 in European Economic Review
Verified
Journal Article
Closed access
DMDavid Miles
David Miles